Background: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma, with median age at diagnosis in the seventh decade. FL in young adults (YAs), defined as diagnosis at ≤40 years, is uncommon. No standard approaches exist guiding the treatment of YA FL, and little is known about their disease characteristics and outcomes. To gain further insights into YA FL, we analyzed the National LymphoCare Study (NLCS) to describe characteristics, initial treatments, and outcomes in this population versus patients aged >40 years.
cell transplant, particularly in the pre-rituximab era [8] [9] [10] . For FL in particular, significant improvements in supportive care and novel treatments have improved overall survival (OS) over the past several years [11, 12] , with median survival in the modern chemoimmunotherapy era approaching two decades [13] . For YA FL patients, few data exist supporting any particular treatment strategy. It is not known whether aggressive upfront approaches are warranted based on presumed clinical or biologic risk, or better tolerance to treatment. Consequently, diagnosis and staging, risk stratification, and treatment are approached heterogeneously, leading to the lack of standardization, potential disparities in care, and plateaus in outcome for the YA FL population [14] .
Our article provides needed insights into the clinical characteristics, treatment, and outcomes of YA FL patients. The unique challenges of cancer care in YAs in the context of a chronic illness merit dedicated research and a full appreciation of the difference between YAs and older adults to optimize treatment outcomes and quality of life. Through the National LymphoCare database, we describe the favorable prognosis of YA FL patients treated with a variety of strategies, and find no support for early aggressive treatment.
patients and methods
The National LymphoCare Study (NLCS) is a prospective, multicenter registry of FL patients in the USA, sponsored by Genentech, Inc. (South San Francisco, CA) and Biogen Idec (Cambridge, MA) [2] . Details of the NLCS have been published elsewhere [15] . Several authors on this article (CMF, CRF, JDH, JRC, BKL, ADZ, and JWF) serve on the NLCS advisory board and have full access to the data for the cohort of patients presented in this analysis. This article was written de novo by the authors, with editorial support from the sponsor. Patients signed informed consent before participating, and an institutional review board approved the protocol. Patients with newly diagnosed FL (within 6 months) between March 2004 and March 2007 and no prior history of lymphoma at participating sites were recruited. There was no central pathology review; the local pathology reports defined FL diagnosis following investigator training on World Health Organization definitions for classification of FL. The cause of death was reported by sites.
Using the NLCS database, we excluded patients with mixed histology or transformed disease at baseline, and defined patient age groups as 18-40 (YA), 41-60, 61-70, 71-80, and >80 years (distribution of age in the entire NLCS cohort is shown in supplementary Figure S1 , available at Annals of Oncology online). Survival [progression-free survival (PFS) and OS] curves, hazard ratios, and corresponding 95% confidence intervals (CIs) were estimated with the adjusted Cox proportional-hazards model by age group. The Cox proportion-hazards model was adjusted for the following four Follicular Lymphoma International Prognostic Index (FLIPI) components: hemoglobin level, lactate dehydrogenase level, number of nodal sites, and disease stage.
results
Of 2652 eligible FL patients in the NLCS, 164 were YAs (6% of the NLCS population), similar to the frequency seen in the NCI Surveillance, Epidemiology and End Results (SEER) program from 2004 to 2007 (the same enrollment period as NLCS; 5% of SEER FL patients were YAs). Median age (range) of the NLCS YAs was 37 (range 22-40) years. Baseline characteristics of YAs were similar to patients aged 41-60 for FLIPI score and most baseline factors, except fewer YAs were of white race and more had a performance score of 0. In addition to race and performance score, differences were observed for YAs versus patients aged >60 in nodal sites, Ann Arbor stage, bone marrow involvement, and treatment center type (Table 1 ). Overall differences among all age groups with respect to histology, stage, and hemoglobin were likely due to difference between the older age groups ( patients aged 41-60 and >60).
First-line therapy for YAs was similar to those aged 41-60 (supplementary Figure S2 , available at Annals of Oncology online). Of the 164 YAs, 46% (n = 76) received first-line rituximab plus chemotherapy (R-chemo); 45/76 patients (59%) received first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Nineteen percent of patients underwent watchful waiting, and 12% received rituximab monotherapy. Among the R-chemo users, R-CHOP use in YAs was similar to patients aged 41-60 (59% versus 55%), but higher than those over 60 (44%; P = 0.007). YAs were more likely to receive 'other' types of therapy (chemotherapy, radiation, radiation plus chemotherapy, investigational therapy, and other therapy) and less likely to receive watchful waiting than patients aged >60.
For the YA FL patient cohort, median PFS was 7.3 years (95% CI 5.6-not reached), and PFS at 2 and 5 years was 75% (95% CI 67-81) and 62% (95% CI 53-70), respectively. With a median follow-up of 8 years, the median OS for YAs was not reached; OS at 2, 5, and 8 years was 98% (95% CI 93-99), 94% (95% CI 89-97), and 90% (95% CI 83-94), respectively. Thirteen YAs (8%) died; five deaths (39%) were lymphoma-related, two (15%) were treatment-related, three (23%) were non-lymphomarelated, and for three (23%) the cause of death was unknown.
Among YAs who had received any active first-line treatment (watchful waiting excluded), 2-year PFS was 76% (95% CI 67- After adjusting for four FLIPI components, PFS for YAs who received any active first-line treatment was similar to patients aged 41-60 and 61-70, and superior to older patients ( Figure 1A and Table 2 ). A similar trend was seen for R-chemo-treated patients ( Figure 1B and Table 2 ), whereas no significant differences were observed between age groups for those who received rituximab monotherapy (R-mono; Figure 1C and Table 2 ). Adjusted OS for YAs who had any active treatment was similar to patients aged 41-60 and superior to older patients ( Figure 1D and Table 2 ). A similar trend was seen for R-chemo-treated patients ( Figure 1E and Table 2 ). For R-mono-treated patients, OS for YAs was similar to those aged 41-60 and 61-70, and superior to older patients ( Figure 1F and Table 2 ). There was no significant difference in outcomes for YAs, compared with other age groups, based on time to transformation across treatments after adjusting for stage, hemoglobin, LDH, and nodal sites. [16] [17] [18] . The rarity of FL in the YA population represents a challenge to a rigorous study in welldesigned clinical trials. Data from our study are strengthened by representation from multiple centers in the USA, with patients treated in the rituximab era. Our results demonstrate good outcomes for YAs, similar to patients aged >40. Our choice to define YA FL as aged ≤40 is predicated on the definition by the NCI, which designates YA cancers as occurring in those aged ≤39. This definition is applied as a national standard in the YA group, with several ongoing clinical trials in various diseases using similar age ranges [19] . Strengths of this study include the well-defined prospective cohort enrolled in the rituximab era, a robust sample size of FL patients aged ≤40, ability to compare with older age groups from the same study, availability of clinical and treatment data, and prospective follow-up of patients for outcomes, including cause of death. There are also limitations. Although we did not conduct central pathology review, we feel this is not likely to impact our conclusions, since previous studies suggest a high rate of accuracy in community diagnosis of FL [20] . We did not have any data on tumor markers, although few are used in routine clinical practice. We also did not have data on comorbidities that could impact treatment choices and outcomes, or data on other outcomes such as second cancers or other potential impacts such as fertility, which future survivorship studies should assess. Finally, our PFS and OS outcomes do not extend beyond a decade, and future work will need to evaluate long-term impacts on FL patients managed in the rituximab era. In general, cancer in YA occurs infrequently, yet it remains the leading disease-specific cause of death in this population [21] . YAs represent ∼5% of FL diagnoses (6% in NLCS and 5% in SEER [22] ). Consequently, novel insights into the YA FL population have lagged in comparison with our advances in knowledge of other NHL and FL in particular [23] . Unlike improvements in survival outcomes observed in children and older adults with cancer, survival rates in YAs with cancer have not achieved the same progress based in part on limited research conducted in this population. Due to the lack of progress in outcomes for YAs with cancer, the NCI designated this group as vulnerable [24, 25] . Moreover, advancing outcomes for YAs has been hindered by limited access to and participation in clinical trials, inconsistency in treatment and follow-up, and limited psychosocial resources and services with a focus on issues important for YAs. For the majority of patients, FL has a continuous rate of relapse, though a small proportion of patients have long-term disease control (or potential cure) with chemoimmunotherapy or transplant [26] . However, in the population of YAs with an otherwise long life expectancy, this prospect is daunting, since they will likely experience the disease recurrences, toxicity, and potential for transformation that may ultimately claim their life. Hence, the impact of reduced life expectancy and chronic illness is particularly relevant for YAs. Until now, it was unknown whether the clinical and biologic characteristics of FL in YA were similar to those in older patients, and whether a different treatment approach was necessary or justified. A clinic-pathologic study of heterogeneously treated YA FL patients found similarities with older adults, with regard to grade, histologic appearance, and immunohistochemical expression [16] . In contrast, children and adolescents with FL are enriched for the pediatric FL type, which demonstrates blastoid cytological features, higher grade and proliferation rate, lack of t(14;18), and a favorable prognosis [27, 28] .
Our data demonstrated few differences in baseline clinical characteristics between YAs and adults older than 40, apart from race and Eastern Cooperative Oncology Group Performance Score (ECOG PS; Table 1 ). After adjusting for FLIPI components, YA FL patients who required front-line treatment did not appear to have an advantage in PFS compared with older adults up to age 70. As may be expected however, both PFS and OS were superior in YAs compared with adults aged >70. The similar OS between YAs and patients aged 41-60 suggests a similar prognosis between both groups once diagnosed, with no signal that YAs are sicker or worse than the average FL patient. Similarly, our data show that first-line therapy for YAs was similar to those aged 41-60 years. Nearly half of all YAs received first-line rituximab plus chemotherapy, most of which consisted of R-CHOP, a finding consistent with patterns of chemoimmunotherapy delivery to patients with FL in the NLCS, and reflective of use in the USA [29] .
As survival after NHL treatment has increased greatly over the past several years, so have secondary risks from therapy, including cardiopulmonary toxicity, reproductive risks, chronic fatigue, and second cancers [30] [31] [32] . A large Nordic registry series of nearly 61 000 NHL survivors found risks of many secondary cancers, the incidence of which were highest among NHL patients diagnosed before age 40. An increase in the incidence of breast cancer was particularly pronounced and the excess risk appeared to be largely confined to those diagnosed before age 40 years [33] . Similarly, a study with 10-year followup of 748 patients treated for aggressive NHL in successive EORTC (European Organization for Research on Treatment of Cancer) trials demonstrated a 4% risk of second cancers, the risks of which appeared age-related, with high risks observed for secondary leukemia, Hodgkin's lymphoma, colorectal cancer, and lung cancer [34] . Given that most YA FL patients become long-term survivors, the minimization of late effects is an important aspect of treatment planning. The secondary risks of death from causes other than lymphoma highlight the importance of preserving health and quality of life in these young patients. Aggressive treatment strategies have previously been used in young patients with FL and other NHL, including stem cell transplant [8] [9] [10] . However, based on our data, there does not appear to be an early indication for this in most YA FL patients.
It may be that YA FL patients may have a favorable biology accounting for its behavior, such as lack of B-cell lymphoma 2 (BCL2) mutations at diagnosis, the presence of which was recently found to correlate with an increased risk of death due to lymphoma [35] ; or alternatively, the presence of intact p53, [36] . Similarly, the possibility of overlap with pediatric FL cannot be excluded in this dataset. Since our data are limited by the lack of central pathologic review, we cannot establish biologic correlates for the clinical phenotype observed in YA FL patients. Ultimately, further study will be required to understand the basis of this possible favorable biology. In summary, YAs with FL have similar outcomes to patients aged 41-60. Fertility preservation and survivorship issues should be taken into consideration when defining management strategies, but otherwise YAs with FL should be approached similarly to older adults with the same disease.
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